| Patient | Charlotte Brontë |
|---|---|
| Date of birth | 1987-04-21 |
| Identifiers | MRN HR-NI025-SYN; SSN (made up) 000-25-3804 |
| Document date | 2026-03-24 |
| Author | Eleanor Thwaite, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 17 weeks. [S]
Ms. Brontë returns at 17 weeks 1 day. She has not vomited for ten days and has needed no ondansetron for two weeks. Mild nausea comes on only when she is tired. She eats well and walks out most afternoons. She takes doxylamine-pyridoxine four tablets a day, aspirin 81 mg at bedtime without bruising or bleeding, and folic acid. Her PUQE-24 score is 4. She has no palpitations, headache, visual change, pain, bleeding, or urinary symptoms. She is writing most mornings and feels hopeful. [S]
| Element | Detail |
|---|---|
| Interval change | No vomiting for ten days; no ondansetron for two weeks |
| PUQE-24 | 4 (mild), down from 14 at its worst |
| Medications | Doxylamine-pyridoxine four tablets a day, aspirin 81 mg, folic acid |
| Mood | Hopeful; EPDS 5 |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No vomiting; mild nausea only when tired; bowels regular |
| Cardiovascular | Negative | No palpitations |
| Neurological | Negative | No headache or visual change |
| Genitourinary | Negative | No bleeding or urinary symptoms |
| Psychiatric | Negative | Mood good; EPDS 5 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) | One tablet by mouth daily | Oral route | 2026-01-13 | active | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets by mouth at bedtime | Oral route | 2026-01-13 to 2026-01-20 | completed | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) | One tablet in the morning, one mid-afternoon, and two at bedtime | Oral route | 2026-01-20 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before meals | One tablet by mouth three times a day, 30 minutes before meals | Oral route | 2026-01-20 to 2026-01-29 | completed | S |
| Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours | 1000 mL over 8 hours, guided by daily electrolytes | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Thiamine 100 mg intravenously daily, the first dose before any dextrose | 100 mg intravenously once daily; first dose before any dextrose-containing fluid | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Ondansetron 4 mg intravenously every 8 hours | 4 mg by slow intravenous injection every 8 hours | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg) | 20 mg (0.2 mL) subcutaneously once daily while in hospital | Subcutaneous route | 2026-01-29 to 2026-02-01 | completed | S |
| Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once | 2 g intravenously over 1 hour, one dose | Intravenous route | 2026-01-29 to 2026-01-29 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours | One tablet on the tongue every 8 hours | Oral route | 2026-02-01 to 2026-02-24 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet on the tongue up to every 8 hours if needed | Oral route | 2026-02-24 to 2026-03-24 | completed | S |
| Thiamine 100 mg oral tablet, one tablet by mouth three times a day | One tablet by mouth three times a day while intake is poor | Oral route | 2026-02-01 to 2026-02-24 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 2026-02-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-24 | Body height | 152 | cm | S |
| 2026-03-24 | Body weight | 46.2 | kg | S |
| 2026-03-24 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 2026-03-24 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-03-24 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-03-24 | Heart rate | 80 | /min | S |
| 2026-03-24 | Respiratory rate | 14 | /min | S |
| 2026-03-24 | Body temperature | 36.7 | Cel | S |
| 2026-03-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-24 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 11-15.5 g/dL | Normal | S |
| 2026-03-24 | Thyrotropin [Units/volume] in Serum or Plasma | 0.92 | m[IU]/L | 0.2-3 mIU/L | Normal | S |
| 2026-03-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-03-24 | Total score [EPDS] | 5 | {score} | S |
Vital signs recorded on 2026-03-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 46.2 kg |
| Neck | Thyroid not enlarged |
| Abdomen | Fundus midway between the pubic bone and the umbilicus |
| Fetal | Fetal heart 150 per minute by Doppler |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 day | active | confirmed | O09.519 | S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019). |
| Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarum | resolved | confirmed | O21.9 | S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R. |
| Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14 | active | confirmed | O21.1 | S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis. |
| Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment needed | resolved | confirmed | O99.281 | S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PUQE-24 score (recorded in the note; no LOINC code found) | Every visit while nausea and vomiting last | Completed today | 4 (mild) |
| Examination | Weight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydration | Every visit while nausea and vomiting last | Completed today | 46.2 kg, back above her pre-pregnancy weight; pulse 80 |
| Laboratory | TSH and free T4 | In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressed | Completed today | TSH 0.92 mIU/L and free T4 1.1 ng/dL: normal |
| Laboratory | Hemoglobin | At intake and again at 24 to 28 weeks; earlier after hemoconcentration | Completed today | 11.6 g/dL |
| Laboratory | Electrolytes, urea nitrogen, creatinine, and glucose | Until stable on oral intake | Not indicated | Not repeated: normal on oral intake |
| Medication safety | Antiemetic taper | When vomiting has stopped for a week | Completed today | Ondansetron stopped; doxylamine-pyridoxine taper over two weeks |
| Medication safety | Low-dose aspirin | Every visit | Completed today | Taken nightly; no bruising or bleeding |
| Survey | Perinatal mood screen | Each trimester | Completed today | EPDS 5; item 10 scored 0 |
| Imaging | Detailed anatomy scan | At 18 to 22 weeks | Due | Booked for 20 weeks |
| Examination | Blood pressure | Every prenatal visit | Completed today | 108/68 mmHg |
| Examination | Fetal heart | Every prenatal visit | Completed today | 150 per minute by Doppler |
Goal progress:
Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017); Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023)
Follow-up: Anatomy scan in three weeks and prenatal visit in four weeks. [S]